Tirzepatide vs Sermorelin

Reviewed by Gabriel Brocklesby · Last updated

Tirzepatide targets GLP-1 and GIP receptors for metabolic health while sermorelin is a growth hormone secretagogue used in longevity protocols. Compare clinic listings by treatment focus and governance model.

Tirzepatide and sermorelin appear in different clinic categories, so the comparison is primarily about provider focus and oversight. Use this page to contrast metabolic health providers with hormone optimisation clinics.

Tirzepatide

A dual GIP/GLP-1 agonist referenced in metabolic health and weight management listings.

Potential benefits

  • Often part of structured metabolic programmes.
  • Growing adoption across clinics.

Considerations

  • Availability varies by jurisdiction.
  • Requires prescriber oversight.
Best for: Comparing metabolic health providers and their monitoring models.

Sermorelin

A growth hormone–releasing hormone analogue referenced in longevity and hormone optimisation listings.

Potential benefits

  • Common in longevity-focused clinics.
  • Often paired with other secretagogues.

Considerations

  • Evidence and protocols vary widely.
  • Requires clinician-led assessment.
Best for: Evaluating hormone optimisation clinics and their governance standards.
CategoryTirzepatideSermorelin
Directory contextInformational clinic and treatment comparison context.Informational clinic and treatment comparison context.
Common goalsCompare how clinics frame suitability, monitoring, and expected use cases.Compare how clinics frame suitability, monitoring, and expected use cases.
Guidance noteInformational listing only; suitability requires clinician review.Informational listing only; suitability requires clinician review.

Next step

Compare clinics offering these treatments

Use city pages and peptide-specific pages to move from general research into actual provider shortlists. That usually gives a better buying picture than comparing drug names alone.

Related clinics

FeaturedVerified

Menon Health

London, United Kingdom

Menon Health is a Mayfair-based peptide therapy clinic founded by Dr Mukil Menon, a GMC-registered physician and one of the first doctors to prescribe medical peptide therapy in the UK. Before establishing Menon Health, Dr Menon served as UK medical director at Koniver Wellness, launching the clinic at Soho House London. He continues to practise within the NHS alongside his private consultations, ensuring his protocols stay grounded in current medical standards. The clinic offers doctor-led, prescription-based peptide therapy alongside regenerative cell complex treatments, bloods and diagnostics, and IV therapy. All formulations are sourced from GMP-certified, EMA-regulated pharmacies and dispensed as pre-filled pens, vials, or multi-peptide syringes — Menon Health's approach to combining multiple peptides in a single dose is designed to improve precision and patient adherence. Based at 64 North Row in Mayfair, London, Menon Health serves patients across the UK, Europe, Canada, and the United States, with consultations available in person or remotely.

In personRemoteFrom £195Virtual consultations
View ProfileSend EnquiryCompare

Conclusion

Pick the clinic type that aligns with your goal. The strongest signal is the provider’s clinical process and monitoring, not the peptide name.

Related peptide pages

US city pages

For clinics

Are you a clinic?

Get featured on this page and reach patients actively looking for peptide therapy, GLP-1 treatments, recovery support, and longevity care.